


Could angiotensin-converting enzyme I *I/D* polymorphism be a modifier of COVID-19 response in different populations, diseases, and/or conditions?

Journal of the Renin-Angiotensin-Aldosterone System
 July-September 2020: 1–2
 © The Author(s) 2020
 Article reuse guidelines:
sagepub.com/journals-permissions
 DOI: 10.1177/1470320320957157
journals.sagepub.com/home/jra


Sanja Dević Pavlič¹ , Sergej Nadalin¹,
 Nada Starčević Čizmarević¹, Alena Buretić-Tomljanović¹,
 Anđelka Radojčić Badovinac^{1,2} and Smiljana Ristić¹

Dear Editor,

Several articles recently discussed the potential relevance of the insertion/deletion (*I/D*) polymorphism in the angiotensin-converting enzyme 1 (*ACE1*) gene to COVID-19 infection.^{1–4} Their data raise the possibility that the *ACE1 D* allele might be a protective factor in the spread and outcome of COVID-19 in various European, North-African, and Middle Eastern populations.^{1–3} However, data presented in the meta-analysis investigating the frequency of *ACE1 D* allele distribution in various European countries revealed that the frequency of that allele was the highest in the countries most severely affected by COVID-19 infection, such as Spain, Italy, and UK.⁵ Specifically, the frequency of *ACE1 D* allele in Spanish, Italian, and UK general population was estimated at 63%, 58%, and 53%, respectively, while the total number of cases and deaths per million to date were 6328 and 606 for Spain, 3975 and 575 for Italy, and 4584 and 642 for UK.⁶ Those data suggest that higher frequency of the *ACE1 D* allele might be rather risk than protective factor in COVID-19 infection. Importantly, higher frequencies of *ACE1 D* allele in general Spanish, Italian, and UK populations are also accompanied by higher frequencies among the elderly individuals, who are at the same time the most vulnerable to COVID-19 infection.⁵ In line with this, the relatively low frequency of the *ACE1 D* allele, estimated at 49%, observed in the general Croatian population⁵ might explain the rather favorable epidemiological situation in Croatia related to COVID-19 infection. Specifically, since the February 25 outbreak of the COVID-19 pandemic in Croatia, the total number of cases per million to date is 656, while total number of deaths per million is 26, suggesting that Croatia has been rather successful in overcoming COVID-19.⁶

In the past 15 years, our study groups have been investigating the possible relevance of the *ACE1 I/D* polymorphism in various diseases and/or conditions in

the Croatian population. Most of our studies suggest that the *ACE1 D* allele as well as the *ACE1 D/D* genotype may be risk factors in multiple sclerosis,^{7,8} schizophrenia,⁹ and lung cancer.¹⁰ Importantly, we have also found that the risk effects of the *ACE1 D* allele and *ACE1 D/D* genotype were in general more prominent among male patients with multiple sclerosis^{7,8} and schizophrenia.⁹ Indeed, COVID-19 infection has previously been associated with sex,¹¹ and a recent article discussing the angiotensin-converting enzyme 2 (encoded by the *ACE2* gene), which has been known to cooperate with *ACE1* in the renin-angiotensin system, hypothesizes that sex differences in COVID-19 severity may be related to the *ACE1* and *ACE2* genes.⁴

The aim of this communication is to emphasize the need for further investigation of the relevance of *ACE1 I/D* polymorphism in COVID-19 infection in different populations. Studies on the potential role of *ACE1 I/D* polymorphism in COVID-19 infection among individuals with different diseases and/or conditions are also warranted. Finally, it would be interesting to address the effect of *ACE1 I/D* polymorphism on COVID-19 infection based on age and sex as a confounders.

ORCID iD

Sanja Dević Pavlič  <https://orcid.org/0000-0001-8440-1722>

¹Department of Medical Biology and Genetics, Faculty of Medicine, University of Rijeka, Croatia

²Department of Biotechnology, University of Rijeka, Croatia

Corresponding author:

Sanja Dević Pavlič, Department of Medical Biology and Genetics, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, Rijeka 51000, Croatia.

Email: sanja.devic@uniri.hr



References

1. Delanghe JR, Speeckaert MM and De Buyzere ML. COVID-19 infections are also affected by human ACE1 D/I polymorphism. *Clin Chem Lab Med* 2020; 58(7): 1125–1126.
2. Saadat M. No significant correlation between ACE Ins/Del genetic polymorphism and COVID-19 infection. *Clin Chem Lab Med* 2020; 58(7): 1127–1128.
3. Delanghe JR, Speeckaert MM and De Buyzere ML. ACE Ins/Del genetic polymorphism and epidemiological findings in COVID-19. *Clin Chem Lab Med* 2020; 58(7): 1129–1130.
4. Gemmati D, Bramanti B, Serino ML, et al. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? *Int J Mol Sci* 2020; 21: E3474.
5. Zajc Petranović M, Skarić-Jurić T, Smolej Narančić N, et al. Angiotensin-converting enzyme deletion allele is beneficial for the longevity of Europeans. *Age (Dordr)* 2012; 34(3): 583–595.
6. <https://www.worldometers.info/coronavirus/> (accessed 29 June 2020).
7. Lovrečić L, Ristić S, Starčević-Cizmarević N, et al. Angiotensin-converting enzyme I/D gene polymorphism and risk of multiple sclerosis. *Acta Neurol Scand* 2006; 114(6): 374–377.
8. Ristić S, Starčević Čizmarević N, Lavtar P, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon- β treatment response in multiple sclerosis patients: a preliminary report. *Pharmacogenet Genomics* 2017; 27(6): 232–235.
9. Nadalin S, Buretić-Tomljanović A, Rubeša G, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism is not associated with schizophrenia in a Croatian population. *Psychiatr Genet* 2012; 22(5): 267–268.
10. Dević Pavlič S, Ristić S, Flego V, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphism in lung cancer patients. *Genet Test Mol Biomarkers* 2012; 16: 722–725.
11. Ambrosino I, Barbagelata E, Ortona E, et al. Gender differences in patients with COVID-19: a narrative review. *Monaldi Arch Chest Dis* 2020; 90: 318–324.